GlassScriptPhysician profile
Kenneth S Johnson
NPI 1558378265
$1,325.51
in general payments reported to CMS, 2019-2025
15 companies · $763 in 2025
The $763 reported for 2025 was more than what 94% of Emergency Medical Services providers received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $562 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.62 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $676.02 | 2024-2025 | Otezla, Otezla, Repatha |
| Novo Nordisk INC | $106.39 | 2024-2025 | Wegovy |
| Eisai INC. | $102.33 | 2024-2025 | |
| Glaxosmithkline, LLC. | $94.04 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $93.82 | 2024-2025 | Xyosted |
| Abbvie INC. | $42.69 | 2024 | |
| Pfizer INC. | $40.53 | 2025 | |
| Novartis Pharmaceuticals Corporation | $37.75 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $22.08 | 2024 | Gemtesa |
| Ibsa Pharma INC. | $20.06 | 2025 | Tirosint, Licart, Flector |
| Astrazeneca Pharmaceuticals LP | $19.03 | 2025 | Breztri |
| Lilly USA, LLC | $18.97 | 2025 | Zepbound, Mounjaro |
| Abiomed | $18.87 | 2025 | |
| Tolmar, INC. | $16.56 | 2025 | Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $16.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.